JP2016513664A5 - - Google Patents

Info

Publication number

JP2016513664A5

JP2016513664A5 JP2016502250A JP2016502250A JP2016513664A5 JP 2016513664 A5 JP2016513664 A5 JP 2016513664A5 JP 2016502250 A JP2016502250 A JP 2016502250A JP 2016502250 A JP2016502250 A JP 2016502250A JP 2016513664 A5 JP2016513664 A5 JP 2016513664A5

Authority

JP

Japan

Prior art keywords

antibody

antigen

binding fragment

hepcidin

seq

Prior art date

2014-03-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims description 52
• 239000000427 antigen Substances 0.000 claims description 45
• 102000036639 antigens Human genes 0.000 claims description 45
• 108091007433 antigens Proteins 0.000 claims description 45
• 108060003558 hepcidin Proteins 0.000 claims description 37
• XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims description 30
• 102000018511 hepcidin Human genes 0.000 claims description 30
• 229940066919 hepcidin Drugs 0.000 claims description 30
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
• 230000010437 erythropoiesis Effects 0.000 claims description 16
• 229910052742 iron Inorganic materials 0.000 claims description 13
• 230000013632 homeostatic process Effects 0.000 claims description 11
• 102000003951 Erythropoietin Human genes 0.000 claims description 6
• 108090000394 Erythropoietin Proteins 0.000 claims description 6
• 229940105423 erythropoietin Drugs 0.000 claims description 6
• 208000015181 infectious disease Diseases 0.000 claims description 6
• 238000002347 injection Methods 0.000 claims description 6
• 239000007924 injection Substances 0.000 claims description 6
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
• 208000020075 IRIDA syndrome Diseases 0.000 claims description 4
• 125000000539 amino acid group Chemical group 0.000 claims description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
• 208000018565 Hemochromatosis Diseases 0.000 claims description 3
• 208000007502 anemia Diseases 0.000 claims description 3
• 230000000694 effects Effects 0.000 claims description 3
• 208000027866 inflammatory disease Diseases 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 208000035143 Bacterial infection Diseases 0.000 claims description 2
• 206010017533 Fungal infection Diseases 0.000 claims description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
• 208000031888 Mycoses Diseases 0.000 claims description 2
• 208000036142 Viral infection Diseases 0.000 claims description 2
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
• 238000010255 intramuscular injection Methods 0.000 claims description 2
• 239000007927 intramuscular injection Substances 0.000 claims description 2
• 238000010253 intravenous injection Methods 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 229920001184 polypeptide Polymers 0.000 claims description 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
• 238000010254 subcutaneous injection Methods 0.000 claims description 2
• 239000007929 subcutaneous injection Substances 0.000 claims description 2
• 230000009385 viral infection Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 7
• 101800003308 Hepcidin-20 Proteins 0.000 claims 1
• 101800003310 Hepcidin-25 Proteins 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 description 15
• 239000000203 mixture Substances 0.000 description 10
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 210000004027 cell Anatomy 0.000 description 3
• 239000000539 dimer Substances 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 241000251730 Chondrichthyes Species 0.000 description 1
• 108010008177 Fd immunoglobulins Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 239000013598 vector Substances 0.000 description 1